Pulse Biosciences Surpasses Enrollment Midpoint in AF Study

Pulse Biosciences reports enrollment is ahead of schedule in its NANOPULSE-AF pivotal study, driven by investigator enthusiasm and an intuitive workflow. This could positively impact the company's chances of regulatory approval.